Catawba Capital Management’s AstraZeneca AZN Stock Holding History

Catawba Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$1.23M	Buy	17,515 +1,922	+12%	+$138K	0.29%	79
2018 Q1	$1.09M	Sell	15,593 -90	-0.6%	-$6.23K	0.26%	83
2017 Q4	$1.09M	Hold	15,683	–	–	0.25%	86
2017 Q3	$1.06M	Sell	15,683 -220	-1%	-$13.9K	0.24%	91
2017 Q2	$1.08M	Buy	15,903 +28	+0.2%	+$1.83K	0.25%	91
2017 Q1	$989K	Sell	15,875 -2,520	-14%	-$147K	0.22%	106
2016 Q4	$1M	Sell	18,395 -38	-0.2%	-$2.16K	0.23%	106
2016 Q3	$1.21M	Buy	18,433 +563	+3%	+$36.8K	0.29%	89
2016 Q2	$1.08M	Hold	17,870	–	–	0.26%	95
2016 Q1	$1.01M	Sell	17,870 -1,400	-7%	-$84.1K	0.26%	96
2015 Q4	$1.31M	Sell	19,270 -315	-2%	-$20.7K	0.36%	76
2015 Q3	$1.25M	Buy	19,585 +2,430	+14%	+$160K	0.34%	76
2015 Q2	$1.09M	Hold	17,155	–	–	0.26%	91
2015 Q1	$1.17M	Buy	17,155 +425	+3%	+$29.5K	0.27%	89
2014 Q4	$1.18M	Sell	16,730 -150	-0.9%	-$10.7K	0.27%	90
2014 Q3	$1.21M	Hold	16,880	–	–	0.28%	88
2014 Q2	$1.25M	Sell	16,880 -75	-0.4%	-$5.42K	0.28%	91
2014 Q1	$1.1M	Sell	16,955 -2,130	-11%	-$138K	0.26%	93
2013 Q4	$1.13M	Buy	19,085 +3,545	+23%	+$193K	0.27%	90
2013 Q3	$807K	Buy	+15,540	New	+$781K	0.21%	104

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Catawba Capital Management's AZN Position: Q2 2018 in Review

Catawba Capital Management increased its AstraZeneca (AZN) stake by 12% in Q2 2018, buying an estimated $138K and bringing the position to 17,515 shares worth $1.23M. The position accounts for 0.29% of the portfolio, ranked #79.

Catawba Capital Management first reported a position in AZN in Q3 2013 and has held it in 20 quarters since. The position peaked at $1.31M in Q4 2015. 530 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

Catawba Capital Management held 17,515 shares of AstraZeneca worth $1.23M as of Q2 2018.
Catawba Capital Management bought 1,922 AstraZeneca shares in Q2 2018, an estimated $138K.
AstraZeneca made up 0.29% of Catawba Capital Management's portfolio in Q2 2018, its #79 holding.
Catawba Capital Management first reported a position in AstraZeneca in Q3 2013 and has held it in 20 quarters since.
Catawba Capital Management's AstraZeneca position peaked at $1.31M in Q4 2015.
530 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.